|
rs541458
|
|
Alzheimer's Disease
|
|
0.760 |
GeneticVariation
|
BEFREE |
<b>Background:</b> Phosphatidylinositol binding clathrin assembly protein (<i>PICALM</i>) rs541458 C allele has been identified and validated to be associated with a reduction of Alzheimer's disease (AD) risk.
|
31133980 |
2019 |
|
rs74315408
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Background:</b> In this study, a known <i>PRNP</i> mutation, Val180Ile (c.G538A), was reported in a 58 years old female patient, clinically diagnosed with Alzheimer's disease (AD).
|
31410005 |
2019 |
|
rs9357347
|
|
Alzheimer's Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
<b>Conclusion:</b> This study suggested that rs9357347 reduced the risk of AD by modulating both amyloid-β pathology and neuronal degeneration.
|
31379492 |
2019 |
|
rs671
|
|
Alzheimer's Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b> In conclusion, our meta-analysis indicated that the <i>ALDH2</i> rs671 G>A polymorphism plays an important role in AD development.
|
30984100 |
2019 |
|
rs2333227
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>MPO</i> rs2333227 polymorphism was positively associated with AD risk, especially under the AA+GA vs. GG and A vs. G genetic models (<i>P</i>=0.042, OR=1.719, 95%CI=1.017-2.906; <i>P</i>=0.041, OR=1.582, 95%CI=1.016-2.463).
|
29296208 |
2017 |
|
rs1217691063
|
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>MTHFR</i> C677T TT and CT genotypes had significant associations with AD risk in all ra</span>cial populations (RR = 1.13, <i>p</i> = 0.0047; and RR = 1.12, <i>p</i> < 0.0001 respectively).
|
28085050 |
2017 |
|
rs17125944
|
|
Alzheimer's Disease
|
|
0.830 |
GeneticVariation
|
BEFREE |
(2) Four additional AD risk SNPs were nominally associated with obesity (rs17125944 at FERMT2, pBMI = 4.03 × 10(-05), pBMI corr = 2.50 × 10(-03) ; rs3851179 at PICALM; pBMI = 0.002, rs2075650 at TOMM40/APOE, pBMI = 0.024, rs3865444 at CD33, pBMI = 0.024).
|
24788522 |
2014 |
|
rs3851179
|
|
Alzheimer's Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
(2) Four additional AD risk SNPs were nominally associated with obesity (rs17125944 at FERMT2, pBMI = 4.03 × 10(-05), pBMI corr = 2.50 × 10(-03) ; rs3851179 at PICALM; pBMI = 0.002, rs2075650 at TOMM40/APOE, pBMI = 0.024, rs3865444 at CD33, pBMI = 0.024).
|
24788522 |
2014 |
|
rs2075650
|
|
Alzheimer's Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
(2) Four additional AD risk SNPs were nominally associated with obesity (rs17125944 at FERMT2, pBMI = 4.03 × 10(-05), pBMI corr = 2.50 × 10(-03) ; rs3851179 at PICALM; pBMI = 0.002, rs2075650 at TOMM40/APOE, pBMI = 0.024, rs3865444 at CD33, pBMI = 0.024).
|
24788522 |
2014 |
|
rs3865444
|
|
Alzheimer's Disease
|
|
0.900 |
GeneticVariation
|
BEFREE |
(2) Four additional AD risk SNPs were nominally associated with obesity (rs17125944 at FERMT2, pBMI = 4.03 × 10(-05), pBMI corr = 2.50 × 10(-03) ; rs3851179 at PICALM; pBMI = 0.002, rs2075650 at TOMM40/APOE, pBMI = 0.024, rs3865444 at CD33, pBMI = 0.024).
|
24788522 |
2014 |
|
rs1049296
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
(2004); J Med Genet 41:261-265] reported that epistatic interaction between rs1049296 (P589S) in the transferrin gene (TF) and rs1800562 (C282Y) in the hemochromatosis gene (HFE) results in significant association with risk for AD.
|
20029940 |
2010 |
|
rs1800562
|
|
Alzheimer's Disease
|
|
0.090 |
GeneticVariation
|
BEFREE |
(2004); J Med Genet 41:261-265] reported that epistatic interaction between rs1049296 (P589S) in the transferrin gene (TF) and rs1800562 (C282Y) in the hemochromatosis gene (HFE) results in significant association with risk for AD.
|
20029940 |
2010 |
|
rs4836133
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
(3) SNPs at two of the obesity risk loci (rs4836133 downstream of ZNF608; pAD = 0.002 and at rs713586 downstream of RBJ/DNAJC27; pAD = 0.018) were nominally associated with AD risk.
|
24788522 |
2014 |
|
rs713586
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
(3) SNPs at two of the obesity risk loci (rs4836133 downstream of ZNF608; pAD = 0.002 and at rs713586 downstream of RBJ/DNAJC27; pAD = 0.018) were nominally associated with AD risk.
|
24788522 |
2014 |
|
rs7493
|
|
Alzheimer's Disease
|
|
0.030 |
GeneticVariation
|
BEFREE |
(3-8) The importance of cardiovascular risk factors in the pathomechanism of Alzheimer's disease (AD) and vascular dementia (VD)(9-13) prompted us to examine the genetic effect of PON2 gene codon 311 (Cys-->Ser; PON2*S) polymorphism and the relationship between the PON2*S allele and the other dementia risk factor, the apoE polymorphism in these dementias.
|
11803456 |
2002 |
|
rs4756
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
14 SNPs showed no variability in AD and control populations, while two SNPs rs4756 and rs2228162 showed the three genotypes.
|
23241556 |
2013 |
|
rs2228162
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
14 SNPs showed no variability in AD and control populations, while two SNPs rs4756 and rs2228162</span> showed the three genotypes.
|
23241556 |
2013 |
|
rs3132293
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
24S-Hydroxycholesterol CSF and plasma levels were also influenced by rs3132293 (CSF: P= 0.004; plasma: P= 0.001) and the TGC haplotype (CSF: P= 0.004; plasma: P= 0.002); this effect was most pronounced in AD patients (rs3132293: CSF: P= 0.009, plasma: P= 0.002; TGC haplotype: CSF: P= 0.019, plasma: P= 0.005).
|
19374686 |
2009 |
|
rs6313
|
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease.
|
15211529 |
2004 |
|
rs63751163
|
|
Alzheimer's Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
Alzheimer's disease presenilin-1 exon 9 deletion and L250S mutations sensitize SH-SY5Y neuroblastoma cells to hyperosmotic stress-induced apoptosis.
|
10658639 |
2000 |
|
rs63750424
|
|
Alzheimer's Disease
|
|
0.080 |
GeneticVariation
|
BEFREE |
Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation.
|
18284428 |
2008 |
|
rs5848
|
|
Alzheimer's Disease
|
|
0.080 |
GeneticVariation
|
BEFREE |
Alzheimer's Disease Neuroimaging Initiative cohort (ADNI; n=237) data, combining both multiplexed proteomics CSF and genotype data, were used to assess the association between CSF analytes and risk SNPs in four genes (SNPs): GRN (rs5848), TMEM106B (rs1990622), ABCC9 (rs704180), and KCNMB2 (rs9637454).
|
28189700 |
2017 |
|
rs1990622
|
|
Alzheimer's Disease
|
|
0.030 |
GeneticVariation
|
BEFREE |
Alzheimer's Disease Neuroimaging Initiative cohort (ADNI; n=237) data, combining both multiplexed proteomics CSF and genotype data, were used to assess the association between CSF analytes and risk SNPs in four genes (SNPs): GRN (rs5848), TMEM106B (rs1990622), ABCC9 (rs704180), and KCNMB2 (rs9637454).
|
28189700 |
2017 |
|
rs704180
|
|
Alzheimer's Disease
|
|
0.020 |
GeneticVariation
|
BEFREE |
Alzheimer's Disease Neuroimaging Initiative cohort (ADNI; n=237) data, combining both multiplexed proteomics CSF and genotype data, were used to assess the association between CSF analytes and risk SNPs in four genes (SNPs): GRN (rs5848), TMEM106B (rs1990622), ABCC9 (rs704180), and KCNMB2 (rs9637454).
|
28189700 |
2017 |
|
rs9637454
|
|
Alzheimer's Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Alzheimer's Disease Neuroimaging Initiative cohort (ADNI; n=237) data, combining both multiplexed proteomics CSF and genotype data, were used to assess the association between CSF analytes and risk SNPs in four genes (SNPs): GRN (rs5848), TMEM106B (rs1990622), ABCC9 (rs704180), and KCNMB2 (rs9637454).
|
28189700 |
2017 |